(Reporting by Aishwarya Nair in Bengaluru; Editing by Toby Chopra) (The day Alexion announced its acquisition of Portola Pharmaceuticals in May, its stock fell sharply, signaling investor discontent with the deal.). Unlike some other leading vaccine candidates, including those from Pfizer and Moderna, the AstraZeneca offering can be quickly produced in vast quantities, would cost only a few dollars per dose and is easy to store for long periods. Based on AstraZeneca’s reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39 billion or $175 per share. AstraZeneca, which is headquartered in Cambridge, England, has turned its focus in recent years to cancer treatments, after its previous best-selling drugs, like the cholesterol treatment Crestor, lost their patent protections. Cambridge, England-based pharmaceutical company AstraZeneca, which is involved in development of a COVID-19 vaccine, said Saturday Dec, 12, 2020, it is acquiring Boston-based drug developer Alexion Pharmaceuticals Inc. in a deal worth dollars 39 billion. The deal for Alexion will help AstraZeneca expand in another sector: immunology, where treatments can be highly lucrative for their makers. Based on AstraZeneca's closing price on Friday, Alexion shareholders are in line to receive about $175 per share. We’re motley! One of the largest pharmaceutical deals in recent years is also one of the most curious. The offer represents a 45% premium to Alexion's share price prior to the announcement of the deal. After the deal being announced on December 12th, 2020, the $39bn acquisition of Alexion by AstraZeneca is now almost complete. If regulators don't try to halt the deal, Alexion shareholders will own around 15% of a much larger AstraZeneca by this time next year. This deal will give AstraZeneca Soliris and its successful follow-on treatment Ultomiris, treatments for rare diseases that involve overactive immune systems intent on bursting important blood cells for no good reason. Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer. The deal values Alexion Pharmaceuticals at $175 per share, a 45% premium to its closing price on Friday at around $121 apiece. AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion Alexion shareholders will receive a big premium in a combination of cash and AstraZeneca stock. Alexion would pay AstraZeneca a fee of up to $1.2 billion if it completes a deal with another buyer. FILE – In this Jan. 29, 2009 file photo, reflections are seen on a sign outside the global headquarters of AstraZeneca in London. The company would also have to pay AstraZeneca up to $1.2 billion to walk away from the deal. December 24, 2020 - AstraZeneca recently acquired Boston-based rare disease specialist, Alexion Pharmaceuticals, in a $39 billion pharmaceutical acquisition deal. The biggest deal … The offer values Alexion at $175 a share, a 45% premium to the closing price on Friday. As stock markets have soared and debt financing remains cheap because of central bank policies, companies have resumed their quest for growth and scale — including through acquisitions. That amounts to $175 a share, a nearly 45 percent premium to Alexion’s closing price on Friday. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion … Die Alexion-Aktionäre erhalten davon 60 Dollar pro Papier in bar und je 2,1243 Astrazeneca American Depositary Shares (ADS). The deal would represent the biggest transaction in pharmaceuticals since 2019. AstraZeneca ( AZN) and Alexion ( ALXN) $39bn merger information including expected completion date, offer price and contact details are … The acquisition is expected to close in the third quarter of 2021. The acquisition will be immediately core earnings-accretive and value-enhancing, and is aligned with stated capital-allocation priorities. In addition to the successful and growing Soliris/Ultomiris franchise, AstraZeneca will also gain access to treatments for a handful of rare metabolic diseases on pace to generate $840 million in revenue this year. The deal would combine two companies working in very different areas of drug research, with Alexion focused on rare diseases and AstraZeneca … The acquisition is expected to close in the third quarter of 2021. AstraZeneca to Buy Alexion for $39 Billion to Add Rare-Disease Treatments. The British drugmaker on Saturday (December 12) announced it is buying Alexion Pharmaceuticals for $39 billion in cash and stock. ... Astrazeneca’s Alexion deal fails to win over the City Pharmaceutical giant is FTSE 100’s biggest faller. This deal is good news for AstraZeneca shareholders who could use some given recent bad news on its Covid-19 vaccine. The AstraZeneca deal, authorized by each corporations’ boards, is an effective end result within the view of sell-side analysts who adopted Alexion. The British drugmaker on Saturday announced it is buying U.S biotech Alexion Pharmaceuticals, which makes treatment for a rare immune disease, for $39 billion in cash and stock. The combined footprint of the company will enable a broad coverage across, primary, speciality and highly specialised care. Guggenheim’s Yatin Suneja has rated Alexion at Impartial. Despite the COVID-19 pandemic, sales of Alexion's rare disease drugs didn't skip a beat in 2020. The hedge fund has repeatedly criticized Alexion over its business strategy, including multibillion-dollar corporate takeovers that proved disappointing. On Saturday, AstraZeneca announced plans to acquire Alexion Pharmaceuticals for just shy of $40 billion. The deal also includes a break clause in which Alexion would pay AstraZeneca $1.2 billion if the deal is not completed. The deal comes as AstraZeneca is in the final stages of testing a Covid-19 vaccine that it is developing with the University of Oxford, one of the most prominent candidates — but which has also faced questions about its effectiveness. Returns as of 03/14/2021. Toward the end of 2020, AstraZeneca splashed out $39 billion for Alexion to expand its immunology presence. Saturday’s deal by AstraZeneca to buy Alexion Pharmaceuticals brings a franchise in rare immune disorders to Astra, while also bringing to a close a campaign by discontented Alexion … Through the deal for Alexion, the biggest by a health care company this year, AstraZeneca will bolster its offerings for rare diseases like blood disorders. By Ludwig Burger. Notably, the deal will be AstraZeneca’s largest acquisition ever and the biggest pharmaceutical deal of … The subscription details associated with this account need to be updated. By: Louis Matovu, Josh Shah, Kerim Hassan, Jaideep Kallu Deal overview The motivations behind this deal are that both companies share the same dedication to science and innovation to deliver life-changing medicines. It’s the largest deal for AstraZeneca since it was founded in a 1999 combination of British and Swedish … Alexion’s offices in New Haven, Conn. AstraZeneca’s deal for Alexion comes as AstraZeneca is in the final stages of testing a Covid-19 vaccine that it is developing with the University of Oxford. The company would also have to pay AstraZeneca up to $1.2 billion to walk away from the deal. AstraZeneca … has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs. Alexion will own 15% of the combined company. AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. AstraZeneca and University of Oxford's Coronavirus Vaccine Approved in India, Copyright, Trademark and Patent Information. London: AstraZeneca Plc, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39 billion deal for rare-disease specialist Alexion Pharmaceuticals Inc. In connection with the Transaction, AstraZeneca intends to file a registration statement on Form F-4 with the United States Securities and Exchange Commission (SEC), which will include a … AstraZeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a US$39 billion deal, the company said in a statement on Saturday. to partner with the Japanese drug maker Daiichi Sankyo. Alexion Pharma surges 30% on AstraZeneca deal Shares of Alexion Pharmaceuticals Inc. jumped more than 31% on Monday following the news that AstraZeneca PLC is set to acquire the company for $39 billion. FRANKFURT (Reuters) -Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said. AstraZeneca recently agreed to buy Alexion Pharmaceuticals for around $39bn. The boards of both AstraZeneca and Alexion have approved the deal, which is slated to close in the third quarter of 2021. AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. In July, the company agreed to pay up to $6 billion to partner with the Japanese drug maker Daiichi Sankyo on a potential treatment for lung and breast cancers. ... the equity component of the transaction would take place on closure of the deal. On Saturday morning, AstraZeneca (NASDAQ:AZN) announced an agreement to buy Alexion Pharmaceuticals (NASDAQ:ALXN) and its line of treatments for rare diseases for $39 billion in a combination of cash and stock. * AstraZeneca (AZN) to pay $60 in cash, $115 in equity per Alexion share* To finance equity component with capital increase * Expects deal to immediately boost core earnings (Adds details) By Ludwig Burger. AstraZeneca is buying Alexion Pharmaceuticals for $39 billion in stock and cash, its largest deal ever. The company said it expected to incur a one-time cash cost of $650 million to realize the synergies. “Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases,” Pascal Soriot, AstraZeneca’s chief executive, said in a statement. Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The deal comes in a week that AstraZeneca … For AstraZeneca, the acquisition is a major shift, catapulting the British pharma giant to the upper ranks of rare disease drugmaking. has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs. FRANKFURT (Reuters) -Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion (NASDAQ: ALXN) Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The proposed deal values Alexion at a premium of 45% above its prior share price. Jede ADS verbrieft wiederum eine halbe Stammaktie von Astrazeneca. Cumulative Growth of a $10,000 Investment in Stock Advisor, AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion @themotleyfool #stocks $AZN $ALXN, Why AstraZeneca May Dominate the European Vaccine Market, Here's What Investors Need to Know About the Sputnik V Coronavirus Vaccine. Astrazeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday. By Itai Almogy, Gaspard Baroudel, Raphael Berz (Yale University), and Nathan Walemba (Oxford University) Overview of the deal Acquirer: AstraZeneca PLC Target: Alexion Total Transaction Size: $39 Billion Closed date: Q3 2021 Target advisor: Bank of America Only after 80 days since the deal being announced, the $39bn acquisition of Alexion by AstraZeneca is now complete. LONDON — The drug maker AstraZeneca agreed on Saturday to buy Alexion, a biopharmaceutical company, for $39 billion in cash and stock, as corporate giants resume big-ticket takeovers, even amid the pandemic. AstraZeneca chief Pascal Soriot told reporters on … The two announced in late November that their coronavirus vaccine appeared to be up to 90 percent effective.